← Back to Clinical Trials
Recruiting NCT07067619

NCT07067619 Pain Acceptance Training in Patients Experiencing Emotional Distress and Somatic Symptoms: Examination of Dialectical Thinking as a Mediating Factor

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07067619
Status Recruiting
Phase
Sponsor University of Haifa
Condition Chronic Pain
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-12-01
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Pain-acceptance intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2024-12-01 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Somatic symptoms, including physical pain, are highly prevalent among mental health patients. Current treatments have limited effectiveness for these symptoms, primarily because of patients' diminished introspective capacity and lack of emotional awareness. The current study proposes pain acceptance training as a new intervention. This intervention relies on the tenets of dialectical thinking, particularly on maintaining a dialectic perspective - at once acknowledging both the desire to end the pain and the ability to accept it as it is. We aim to examine the following: (1) the efficacy of pain acceptance training in the alleviation of somatic pain in patients with somatic symptoms; (2) the role of dialectical thinking as a mediator of pain acceptance training efficacy.

Eligibility Criteria

Inclusion Criteria: 1. Men and Women 2. Aged 18-70 3. Able to provide a signed informed consent 4. Experiencing significant pain symptoms that interfere with daily-life functioning 5. Experiencing significant emotional distress symptoms Exclusion Criteria: Patients under the age of 18 and/or diagnosed with one or more of the following diagnoses will be excluded from participation in the study: 1. Patients rating their average pain in the last week and in the last month as less than 3 in a 0-10 numerical rating scale (i.e. NPS) 2. Patients rating their emotional distress levels as less than 25 in a 10-50 numerical rating scale (i.e. Kessler Psychological Distress Scale \[K10\]) 3. Patients diagnosed with psychotic disorders and/or suffering from psychotic symptoms. 4. Patients diagnosed with Autism Spectrum disorder. 5. Patients diagnosed with Intellectual disability. 6. Patients diagnosed with eating disorders. 7. Patients with Immediate suicidal risk. 8. Patients who initiated a new drug and/or psychotherapy treatment within the last month. 9. Pregnant women. 10. Patients currently serving in the IDF.

Contact & Investigator

Central Contact

Sulamit Grinapol

✉ s_grinapol@rambam.health.gov.il

📞 +972 047771718

Frequently Asked Questions

Who can join the NCT07067619 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07067619 currently recruiting?

Yes, NCT07067619 is actively recruiting participants. Contact the research team at s_grinapol@rambam.health.gov.il for enrollment information.

Where is the NCT07067619 trial being conducted?

This trial is being conducted at Haifa, Israel, Haifa, Israel.

Who is sponsoring the NCT07067619 clinical trial?

NCT07067619 is sponsored by University of Haifa. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology